A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?

Leuk Lymphoma. 2010 May;51(5):737-8. doi: 10.3109/10428191003715377.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Cyclophosphamide / adverse effects
  • Doxorubicin / adverse effects
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Pneumocystis carinii / isolation & purification*
  • Pneumonia, Pneumocystis / chemically induced*
  • Pneumonia, Pneumocystis / drug therapy
  • Prednisone / adverse effects
  • Rituximab
  • Treatment Outcome
  • Vincristine / adverse effects

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol